QURE WACC - Weighted Average Cost of Capital
The WACC of Uniqure NV (QURE) is 10.4%.
| Range | Selected | |
| Cost of equity | 9.6% - 12.5% | 11.05% |
| Tax rate | 1.0% - 1.1% | 1.05% |
| Cost of debt | 7.0% - 12.0% | 9.5% |
| WACC | 8.6% - 12.3% | 10.4% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 1.24 | 1.37 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 9.6% | 12.5% |
| Tax rate | 1.0% | 1.1% |
| Debt/Equity ratio | 0.61 | 0.61 |
| Cost of debt | 7.0% | 12.0% |
| After-tax WACC | 8.6% | 12.3% |
| Selected WACC | 10.4% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| QURE | Uniqure NV | 0.61 | 1.64 | 1.02 |
| ARQT | Arcutis Biotherapeutics Inc | 0.07 | 0.83 | 0.77 |
| CYDY | Cytodyn Inc | 0.07 | 0.88 | 0.82 |
| CYTK | Cytokinetics Inc | 0.18 | 1.01 | 0.86 |
| OCGN | Ocugen Inc | 0.12 | 1.39 | 1.25 |
| REPL | Replimune Group Inc | 0.1 | 1.92 | 1.74 |
| VBIV | VBI Vaccines Inc | 13.32 | 1.21 | 0.09 |
| ZYME | Zymeworks Inc | 0 | 1.39 | 1.39 |
| ARGX.BR | argenx SE | 0 | 0.92 | 0.92 |
| ESP.AS | Esperite NV | 12.71 | 1.32 | 0.1 |
| Low | High | |
| Unlevered beta | 0.84 | 0.96 |
| Relevered beta | 1.36 | 1.55 |
| Adjusted relevered beta | 1.24 | 1.37 |
QURE's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for QURE:
cost_of_equity (11.05%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.24) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.